EAM
BBIO icon

EFG Asset Management’s BridgeBio Pharma BBIO Stock Holding History

EFG Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.18M Buy
99,726
+27,561
+38% +$1.34M 0.67% 49
2025
Q2 		$3.12M Buy
+72,165
New +$2.62M 0.44% 99

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EFG Asset Management's BBIO Position: Q3 2025 in Review

EFG Asset Management increased its BridgeBio Pharma (BBIO) stake by 38% in Q3 2025, buying an estimated $1.34M and bringing the position to 99,726 shares worth $5.18M. The position accounts for 0.67% of the portfolio, ranked #49.

EFG Asset Management first reported a position in BBIO in Q2 2025 and has held it in 2 quarters since. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • EFG Asset Management held 99,726 shares of BridgeBio Pharma worth $5.18M as of Q3 2025.
  • EFG Asset Management bought 27,561 BridgeBio Pharma shares in Q3 2025, an estimated $1.34M.
  • BridgeBio Pharma made up 0.67% of EFG Asset Management's portfolio in Q3 2025, its #49 holding.
  • EFG Asset Management first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 2 quarters since.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.